# Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

> **NCT01194856** · PHASE4 · TERMINATED · sponsor: **The Cleveland Clinic** · enrollment: 1 (actual)

## Conditions studied

- HIV Infection
- Mitochondrial Dysfunction

## Interventions

- **DRUG:** Atazanavir/ritonavir
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT01194856
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Closed due to low enrollment
- **Last updated:** 2017-08-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01194856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01194856, "Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01194856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*